

BIA China Special Interest Group Webinar

Update on China biopharma landscape and partnering opportunities



BIA welcome



Steve Bates
CEO
BioIndustry Association

China Special Interest Group



The China SIG was set up with the China-Britain Business Council (CBBC), and supported by the Department for International Trade (DIT).

- To home in on issues with Britain/China collaboration and investment *specific to biotechnology and early stage companies*
- To provide a network of support and information for companies exploring the possibilities and provide a forum for candid input from group members
- To act as a forum for UK companies to actively engage with UK-China biotech activities and the UK government's business development strategies in the sector. To include details of high-level official visits; conferences & trade shows; missions; seminars; meetings and any other relevant events in the sector
- Ultimately to provide a Forum for UK organisations in the sector to explore the opportunities for them to grow their business in and with China, via trade & investment



Growing Importance of China

- **Regulation** of drugs has changed with a new approach from the Chinese regulator The National Medical Products Administration (NMPA)
- **Re-imbursment** procedures have changed for this huge market
- **Talent** policies to get experienced leaders to return “sea turtles” are working and an ecosystem is developing
- **Capital** and Public Markets
- **Improved Access** to markets

Activities in China

September 2019 - BIA announced major initiative with AstraZeneca and new state of the art lifescience innovation campus in Wuxi China



Activities in China

November 2019 Shanghai, China

BIA supported a UK Investor Track at the China Healthcare Summit. Six member companies came out to present



Activities in China



WuXi Healthcare Forum in Shanghai, March 2019



Boao Forum in Hainan Province, March 2019



Xiamen delegation, September 2019

www.bioindustry.org

Activities in China

Guangxi delegation, December 2019



WuXi Global Forum, January 2020



Covid disruption – maintaining relationships and continued collaboration



Key Learnings from Coronavirus Challenge and Innovating for a Sustainable Future

Zoom Webinar

2nd April, 2020 10:00 – 11:30 (UTC+00:00) / 17:00 – 18:30 (UTC+08:00)



Panel session 3: Reaching China

Qionger He



Shaun Grady



Peter Wrighton-Smith



英国中国商会
China Chamber of Commerce in the UK

The 3rd China-UK Economic and Trade Forum & The Launch Ceremony of '2020 Report on the Development of Chinese Enterprises in the UK'

第三届中英经贸论坛 暨《2020 英国中资企业发展报告》发布会

Covid disruption – maintaining relationships and continued collaboration



Update on Opportunities in China: policy and regulatory changes



Josh Berlin
Executive Director of BD
BioCentury



Hamish King
COO
Cisema



Katherine Wang
Partner
Ropes & Gray



Qun Yang
COO & Co-Founder
Biorbyt Ltd.

Wuxi Healthcare Forum 2021 UK reception

Contact info:
UK BioIndustry Association: Miriam Gedge mgedge@bioindustry.org
Wuxi Apptec Group: Dave Madge dave_madge@wuxiapptec.com
UK Department of International trade: Qionger He qionger.he@fco.gov.uk Tel 008613818204106



www.bioindustry.org

www.bioindustry.org

National Security & Investment Regime



Membership

Events

News

Policy

About Us



National Security and Investment

- Regime came into force on **4 January 2022**
- Applies to transactions on or after 12 November 2020

Sector definition: Synthetic Biology

Exceptions – human or veterinary medicines or immunomodulatory approaches

6.—(1) Exceptions to the activities described in paragraph 2 are the ownership, ownership of intellectual property or development of the matters set out in sub-paragraph (2) that employ synthetic biology at any stage of the development or production, unless the circumstances set out in sub-paragraph (3) apply.

(2) The matters referred to in sub-paragraph (1) are—

- (a) human or veterinary medicines;
- (b) immunomodulatory approaches.

(3) The circumstances referred to in sub-paragraph (1) are where the matter described in sub-paragraph (2)—

- (a) has a synthetic biology technology that could be employed or modified to produce, deliver or produce and deliver—
 - (i) toxic chemicals to achieve an incapacitating or lethal effect on humans or animals;
 - (ii) materials restricted under Schedule 5 to the Anti-terrorism, Crime and Security Act 2001(a); or
- (b) uses substances or pathogens set out in Schedule 5 to the Anti-terrorism, Crime and Security Act 2001.

More information



- ISU can be contacted for informal discussions and to answer any questions: investment.screening@beis.gov.uk



Membership

Events

News

Policy

About Us



National Security and Investment

Going forwards –

“It does not matter how slowly you go so long as you do not stop.” Confucius

- **Strong and stable, an enduring endeavour**
- **Shared Global Agendas – AMR**
- **Pandemic Preparedness**
- **Regulation of new technologies**

Contact



The BioIndustry Association,
7th Floor, Southside,
105 Victoria Street,
London, SW1E 6QT
● Tel: +44 (0)20 7630 2180


BIA China Special Interest Group Webinar Thursday 26 May

Tom Duke
Deputy Trade Commissioner, China
Department of International Trade




Policy reform to meet healthcare needs

- China now one of the fastest countries to launch new medicines
- Faster, better drug approval: 61 in 2021
- Drugs developed overseas account for 49% of 2021 approvals



Building up biotech

- Chinese government pledged to increase R&D spending by 7% a year to 2025
- Seven target areas including: brain science, clinical sciences & healthcare, and genetics & biotechnology




- China's 2020 spend on R&D is at 2.4% of GDP

Funding is available

- Venture capital
- Pharmaceutical companies looking for strategic investments
- High quality assets, facilities, and expertise

Venture Dollar Volume By Country In Asia, Through Q4 2021


Includes seed, venture and private equity to venture-backed companies



crunchbase news

Track record of global partnerships

- Chinese companies are going global, in-licensing *and* out-licensing assets at all phases
- 171 China-inward cross-border licensing deals in 2021
- Top 5 country originators:
 - USA
 - South Korea
 - Japan
 - UK
 - Canada



Department for International Trade (DIT)

- **Individual, bespoke support including:**
 - Licensing and investment
 - Intellectual property, patents
 - Policy, regulatory, business support, exports
- **Partnering British and Chinese companies**
- **Sponsor and host events**



ChinaBio – September 2022, Beijing

informa

CHINABIO
PARTNERING FORUM

2 days in-person. 2 days virtually.
September 13–14, 2022 | Beijing, China
September 15–16, 2022 | Virtual

Home Booking Options What's On? Agenda Event Experience Partnering Opportunities Presenting Companies Sponsors & Exhibitors Who's Going? Attendees Plan Your Visit **BOOK NOW**

2 days in-person. 2 days virtually.
September 13–14, 2022 | Beijing, China,
September 15–16, 2022 | Virtual

**FORGE VALUABLE CROSS-BORDER PARTNERSHIPS
AT CHINABIO® PARTNERING FORUM**

Engage with the largest network of potential partners to accelerate your cross-border strategies and expand your reach into the China market

ChinaBio® Partnering Forum returns to Beijing! 2 days in-person, 2 days virtually. This year's hybrid event enables you to identify, meet and network with leaders across the life science value chain. Access to partneringONE is restricted to registered attendees

Coproduced by **EBD GROUP**

Interested in joining our
virtual delegation?


Contact

ruijia.zhang@fcdo.gov.uk



UK-China Business Connect

The screenshot shows the landing page of the UK-China Business Connect platform. At the top, it features the Department for International Trade logo and navigation links. The main heading is "UK-China Business Connect" with the tagline "Your gateway to the China market." Below this, there are sections for "Why register?", "How can we help you?", and "In China, we achieve this by:". The "Why register?" section includes a "Register now" button. The "How can we help you?" section lists benefits like integrating policy and financial expertise. The "In China, we achieve this by:" section features three icons representing market access, UK business support, and Chinese investor assistance.



The screenshot shows the search results page for "生命科学" (Life Sciences). The page features a search bar at the top and a list of search results. Each result includes a company logo, name, and a brief description in Chinese. The results are organized into a grid layout with a search bar at the top and a list of search results below. The results include companies like FrancaMod, Optbac, Matrix Seating, and Thomson Screening Solutions Ltd.



Our team in China



Gary Hunt – Shanghai
Assistant Director Life Sciences & Healthcare
gary.hunt@fcdo.gov.uk



Win-Yan Chan – Beijing
Head of Pharma
winyan.chan@fcdo.gov.uk



Ruijia Zhang – Chongqing
Senior Trade and Investment Officer
ruijia.zhang@fcdo.gov.uk



Ning Ma – Beijing
Senior Trade and Investment Officer
ning.ma@fcdo.gov.uk



Fang Ma – Beijing (Mat Leave)
Senior Trade and Investment Officer
ma.fang@fcdo.gov.uk






**BIA: Update on China biopharma landscape
and partnering opportunities**

26 May 2022

The background

Overview of Diurnal:

- UK-based, European specialty pharmaceutical company
- Focused on rare and niche endocrine diseases
- Pipeline concentrated on repurposing of existing (off-patent) compounds



Backdrop to China opportunity:

- Convergence of several factors
 - Increased focus on treatment of paediatric disease
 - First National List of Rare Diseases published (May 2018)
 - Lists 121 diseases, CAH amongst them
 - Initiatives around treatment of rare diseases
 - e.g. establishment of Rare Disease Treatment Centre, Hainan



Environment conducive to establishment of new companies focused on rare diseases

The process

- **Change in rare disease backdrop lead to Diurnal being approached by around 20 companies, through:**

- Partnering meetings e.g. BioEurope
- Website directly
- Introductions by DIT



- **Experiences of process:**

- Validation of companies can be challenging (no Companies House)
 - DIT extremely helpful in validation
- Complexity of corporate structures
 - Approached by two companies separately in same group - DIT assisted here
- Local visit highlighted sophistication of distribution networks
- Understanding local regulatory requirements (and changes)
- Board concerns e.g. intellectual property, successor products
- Chinese law vs. English law
 - Access to lawyer with local expertise

The deals

Two deals executed with RareStone (Citrine):

- **Alkindi** (hydrocortisone modified-release hard capsules) (Jan 2021)
 - Exclusive license for China, Hong Kong, Taiwan and Macau
 - Rarestone responsible for further development, regulatory, commercial
 - \$0.5 million upfront
 - Up to \$12.75m milestones
 - Royalties on sales
- **Efmody** (hydrocortisone granules in capsules for opening) (May 2021)
 - Scope as per Alkindi
 - \$1.0 million upfront
 - Up to \$28.75m milestones
 - Royalties on sales



Innovent

Innovent Biologics

BIA CHINA SPECIAL INTEREST GROUP MEETING

Astrid Maria Dahl

Chief Operating Officer and Head, Innovent Biologics (Europe)

MAY 26th 2022



To develop and commercialize high quality biopharmaceuticals that are affordable to ordinary people.

Innovent's First 10 Years Growth: A Solid Track Record



- 2021 total product revenue over RMB 4bn
- Accumulated sales of TYVYT over RMB 6.4bn since launch with continuous satisfactory growth momentum

- 6 assets in NDA or pivotal trials
- 19 assets in Phase I and II stages
- 80+ research programs in pre-clinical stage

- 60K liter capacity in operations. Additional 172K liter capacity under construction
- World-class CMC

- Strategic collaboration with MNCs e.g. Eli Lilly and Roche
- Partnership with regional and global biotechs

- 1,500+ R&D
- 1,300+ CMC
- ~3,000 sales & marketing

Transformed from a biotech start-up to a leading biopharma company in China

Innovent Biologics 2022 – A Global Player



INNOVENT USA – ROCKVILLE, MARYLAND
US HQ - R&D, BD



INNOVENT EUROPE – LONDON
EUROPEAN HQ – BD, REGULATORY, CLIN OPS



Innovent Suzhou (CHINA HQ)
Innovent



Innovent Beijing

Innovent Shanghai
Commercial
From 2023 new R&D HQ



Innovent HK

Building Leading Commercial Franchise with Expanding Approved and Late-stage Portfolio in Near Term

Robust Late Stage Assets for Growth



Broad Patients and Big Market
☆☆☆☆

Oncology/ Non-Oncology

TYVYT®	IBI-362
CYRAMZA®	PCSK9
BYVASDA®	VEGF/C
CTLA-4	

Clear Unmet Need and Good Opportunity
☆☆☆☆

HALPRYZA®	SULINNO®
Pemazyre®	IL-23
Olverembatinib	PDE4
RETSEVMO®	
BCMA CAR-T	
ROS1/NTRK	
PI3Kδ*	

Franchise and Synergy in TAs



Oncology | Metabolic | Autoimmune | Ophthalmology




TA	Target/Asset	Product	Status	Indication
	PD-1 (sintilimab)	TYVYT®	Launched	cHL
	CD20 (rituximab)	HALPRYZA®	Launched	NHL
	BCR/ABL (olverembatinib)	NAILIKE	Launched	CML
	BCMA CART (Equecabtagene Autoleuce)	IBI-326	NDA in 1H2022	MM
	PI3K (parsaclisib)	IBI-376	Pivotal Ph2	FL
	PD-1 (sintilimab)	TYVYT®	Launched	1L sqNSCLC; 1L nsqNSCLC
	PD-1 (sintilimab)	TYVYT®	Launch in 2022	EGFR+ NSCLC
	RET (selpercatinib)	RETSEVMO®	Launch in 2022	RET+ NSCLC
	ROS1 (taletrectinib)	IBI-344	Pivotal Ph2	ROS1+ NSCLC
	KRAS G12C	IBI-351	Ph1	KRAS+ NSCLC
	PD-1 (sintilimab)	TYVYT®	Launched	1L HCC
	VEGF-A (bevacizumab)	BYVASDA®	Launched	1L HCC
	VEGFR2 (ramucirumab)	CYRAMZA®	Launched	2L GC
	CTLA-4 (ipilimumab)	IBI-310	Ph3	1L HCC
	FGFR1/2/3 (pemigatinib)	PEMAZYRE®	Launched	CCA
	PD-1 (sintilimab)	TYVYT®	Launch in 2022	1L GC
	PD-1 (sintilimab)	TYVYT®	Launch in 2022	1L ESCC
	VEGFR2 (ramucirumab)	CYRAMZA®	Launched	2L GC
	KRAS G12C	IBI-351	Ph1	CRC, PC, etc.
	CLDN18.2	IBI-360; IBI-345; IBI-389	Ph1	GC, PC, etc.
	PD-1 (sintilimab)	TYVYT®	Pivotal Ph2	2L CC
	CTLA-4 (ipilimumab)	IBI-310	Pivotal Ph2	2L CC
	VEGF-A (bevacizumab)	BYVASDA®	Launched	OC, CC
	PCSK-9 (tafolecimab)	IBI-306	NDA in 1H2022	nFH, HeFH
	GLP1/GCGR	IBI-362	Ph3 in 2022	Diabetics, Obesity
	TNFα (adalimumab)	SULINNO®	Launched	RA, AS, Psoriasis, PJIA, Uveitis
	IL-23	IBI-112	Ph3 in 2022	Psoriasis; Ulcerative colitis
	PDE4 (orismilast)	IBI-353	Ph3 in 2023	Psoriasis; Atopic Dermatitis
	VEGF/C (efdamrofusp alfa)	IBI-302	Ph2	nAMD

Internally Focus on 7 Major Research Taskforces to Deliver Global Potential Drugs


With the goal to discover, develop and commercialize potential global blockbuster drugs by 2030, we have 80 research programs at pre-clinical stage supported by state-of-the-art protein and antibody engineering technologies.

Innovent Academy Projects
(80 projects & 7 taskforce)


Monoclonal antibody




ADC traditional



ADC ISAC




Multi-specific




T/NK engager



Immuno-cytokine



Pro-drug



Polymeric IgG



Proprietary technology platforms

ADC platform, Bispecific platform, Phage and yeast display platform, Hybridoma platform.....

Global discovery powerhouse

US lab established in 2021



Shanghai R&D center in operations by 2023




BD Strategy is Complementary to Innovent's Globalization Strategy



Strengthen Technical Core-Competency



GLOBAL R&D PLATFORMS



Strengthen Global Product Portfolio



Early/Mid Stage – GLOBAL RIGHTS

In/out-license out opportunities, accelerate US/EU presence

“Next Generation Targets”

- New targeted therapies
- Novel targets
- Validated new targets
- ADC approaches



Late Stage - CHINA RIGHTS

Collaborate on China molecules to synergize with pipeline development and commercialization

“Close to market focus”

- Various validated targets
- Oncology
- Non-oncology (metabolic, ophthalmology, immunology)

Going From Domestic to Global Market



GLOBAL FOOTPRINT

Collaborate with experienced and sophisticated partner

“Establish global brand”

- Maximize the commercial value of product portfolio
- Accelerate to meet the global unmet medical needs with good image

As our BD transactions align with our strategy – we lay a strong path for globalization.

Overview of HitGen

Advancing Innovative Drug Discovery

HitGen Inc. (688222.SH)

May, 2022



Disclaimer

This presentation has been prepared by HitGen Inc.(the “Company”) . The information contained in this presentation is intended for information purpose only and does not take your investment objectives, financial status, and special needs into consideration. This presentation does not constitute legal, regulatory, accounting tax or investment advice to you, or any form of financial opinion or recommendation by the Company or any other party at any time. We recommend that you seek independent third party legal, regulatory, accounting, tax, investment and/or financial advice regarding the contents of this presentation.

The Company is not making any offer of its securities and cannot accept orders for any securities at this time. This presentation does not constitute an offer to sell or issue or a solicitation of any offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied upon in connection with any contract or commitment whatsoever. Specifically, this presentation does not constitute a “prospectus” within the meaning of the Securities Act.

This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. All relevant information relating to the Company should be subject to the information disclosed publicly by the Company. In this presentation, may be cited statistics from the history of public release of the data or information. The information herein is preliminary and subject to change and its accuracy is not guaranteed. The information included herein was obtained from various sources, including certain third parties, and has not been independently verified.

NO REPRESENTATION, WARRANTY OR UNDERTAKING, EXPRESS OR IMPLIED, IS MADE AS TO, AND NO RELIANCE SHOULD BE PLACED ON, THE FAIRNESS, ACCURACY, COMPLETENESS, TIMELINESS, APPROPRIATENESS OR CORRECTNESS OF THE INFORMATION CONTAINED HEREIN. NONE OF THE COMPANY OR ANY OF ITS AFFILIATES, SHAREHOLDERS, DIRECTORS, EMPLOYEES, AGENTS, ADVISORS OR REPRESENTATIVES WILL BE LIABLE FOR ANY LOSS HOWSOEVER ARISING FROM ANY USE OF THIS PRESENTATION OR ITS CONTENTS OR OTHERWISE ARISING IN CONNECTION WITH THIS PRESENTATION OR ITS CONTENTS (INCLUDING BUT NOT LIMITED TO NEGLIGENT REPRESENTATION OR OMISSION).

Unless otherwise instructed by the company in writing, the company is the sole and exclusive owner of all right, title, and interest in and to all the information under this presentation.

About HitGen




- HitGen was founded in 2012, headquartered in Chengdu, China
- Subsidiaries outside China include Vernalis (R&D) Ltd in Cambridge, UK and HitGen Pharmaceuticals Inc. in USA
- HitGen has ~500 employees (20%PhD, 30%MS), >20,000 m² laboratory and office space
- HitGen focuses on **DNA encoded chemical libraries (DELs)**, **fragment-based drug discovery (FBDD)** and **structure-based drug design (SBDD)** technologies, **synthetic therapeutic oligonucleotide(STO)** and **targeted protein degradation (TPD)** offering a full set of research capabilities from target to IND filing and project pipeline in oncology, immunology and inflammation
- HitGen is listed on Shanghai Stock Exchange (688222.SH)

Vernalis (R&D) Limited



>6,000 Protein/Protein-Ligand crystal structures generated – in-house detector and synchrotron access



- ◆ Founded in 1996; Cambridge, UK-based
 - ◆ Full suite of capabilities and facilities for drug discovery
- ◆ One of the world leaders in fragment and structure-based drug discovery
 - ◆ Innovation in adopting and adapting methods, particularly in biophysics
- ◆ A team of ~70, most with over 20 years of drug discovery experience

- ◆ Drug discovery collaborations from target to candidate
 - ◆ 6 development candidates in the past 5 years
 - ◆ 20 families of Joint Patents granted
 - ◆ Disclosed partners include: Asahi Kasei Pharma, Lundbeck, Servier, PhoreMost
- ◆ Multi-target collaborations in Target Enablement
 - ◆ Focus on challenging, novel, previously undrugged targets; disclosed with Servier and Genentech



Corporate Strategy Upgrade


ONE Vision: To build a world-class Innovative biopharmaceutical enterprise and contribute to better life and health of mankind

Two Types of Innovative Drugs: Small molecules; Nucleic acid drugs


Three Business Models: Technical services; Project out-licensing; Product sales

Four Core Technology Platforms: To develop a leading technology matrix with key capabilities for drug discovery and optimization to support continuous innovative drug research, development, and production.

- DNA-encoded library (DEL)
- Fragment-based drug discovery and structure-based drug design (FBDD/SBDD)
- Synthetic therapeutic oligonucleotide (STO)
- Targeted protein degradation (TPD)



HitGen Innovative Drug Discovery Research Platform




DEL: DNA-Encoded Library **FBDD/SBDD:** Fragment-Based Drug Discovery and Structure-Based Drug Design **STO:** Synthetic Therapeutic Oligonucleotide **TPD:** Targeted Protein Degradation

Business development underpinned by strong R&D investment



DNA Encoded Library Size



Note 1: HG146 capsule, a selective HDAC inhibitor.
 Note 2: HG030 tablet, 2nd generation NTRK inhibitor
 Note 3: HG381, phase I STING non-CDN agonist



Expanding Drug Discovery Pipeline (2021)

Around **20** in-house drug discovery projects at different stages. Four programmes received NMPA's approvals of IND and are in Phase I clinical study.

HG030

New-generation inhibitor for Trk/ROS1. HitGen's first project receiving IND approvals by both NMPA and FDA to conduct clinical trials.

HG146

A selective small molecule inhibitor for Class I/IIb HDAC. Multiple Myeloma (MM).

HG146

A selective small molecule inhibitor of Class I/IIb HDAC. Solid tumor.

HG381

A non-nucleotide STING agonist. Multiple advanced solid tumors.



HG030

Target:	NTRK/ROS1 Inhibitor
Indication:	Solid Tumor
Clinical Trial Stage:	Phase I
IND application approved from FDA in Jan. 2022	



HG146

Target:	I/IIa HDAC Inhibitor
Indication:	Multiple Myeloma & Solid Tumor
Clinical Trial Stage:	Phase I




HG381

Target:	STING Agonist
Indication:	Solid Tumor
Clinical Trial Stage:	Phase I




HitGen Business Models



DELs: DNA Encoded libraries; FBDD/SBDD: Fragment-Based Drug Discovery/Structure-Based Drug Design
STO: synthetic therapeutic oligonucleotide; TPD: Targeted Protein Degradation

HitGen Collaboration Partners (in public)



>300
Existing
Partners



>2,000
Potential
Partners



Welcome to Visit us



THANKS!

谢谢聆听



Welcome to visit us by
www.hitgen.com or www.vernalis.com
or scan 2D barcode.

欢迎访问我们的网站：
www.hitgen.com or www.vernalis.com
或扫描左侧的二维码





A National credit
endorsement business
partner for Chinese market

Since 1984
Meheco is here in China for you!

中国医药保健品有限公司
CHINA MEHECO CORPORATION

2022



Industry Position



Administration Commission of the State Council (SASAC)

Backbone state-owned enterprise directly administered by the central government



China General Technology (Group) Holding Co., Ltd.

Genertec's main platform of medicine & medical devices business



China Meheco Group Co., Ltd. (Stock Code: 600056)

China Meheco - Main International Platform (import and export)

中国医药

China Meheco Corporation

- Three main activities: advanced manufacturing & technical service, medicine & medical health, international trade & engineering service
- **Rank No. 430 in the Fortune Global 500**
- One of the three centrally-administered state-owned enterprises in medicine & medical industry in China
- **Over 330 medical institutions, over 46,000 beds, over 26 million outpatient service times per year**
- One of the three centrally-administered state-owned enterprises in medicine and medical industry in China in the A shares market
- **Ranked 3rd in the Top 100 Chinese Medicine and Health Products Import and Export Enterprises**
- Window of "Bring in" and "Go global" strategy of China Meheco
- **Undertakes the mission of National Pharmaceutical Stockpile and special medicine import business. Chinese outstanding enterprise in the fight against the COVID-19 epidemic.**
- **Ranked 2nd in the Top 100 Chinese Medicine Import Enterprises**

Genertec's Medical Institution Landscape in China

Genertec has established a national landscape of medical institutions in China, and has become a **centrally-administered state-owned medical group leading in bed number, Internet facility and industry chain building.**

Till May 2022,



330 medical institutions in **26** provinces in China (include **27** Grade 3 hospitals, **69** Grade 2 hospitals)




over **46,000** beds



over **26 million** times of outpatient services per year

通用医疗机构覆盖分布情况
Genertec's medical institution landscape in China





Corporate Structure

Genertec

中国通用技术(集团)控股有限责任公司
CHINA GENERAL TECHNOLOGY (GROUP) HOLDING, LIMITED

Fortune Global 500 company



中国医药健康产业股份有限公司
CHINA MEHECO GROUP CO.,LTD.

Unique platform under Genertec in health field

International Business

China Meheco Corporation

Professional international business and government project platform of China Meheco Group

Pharmaceutical Industry


8 Factories

4 Chemical drug plants
3 Traditional Chinese drug plants
1 Bio-product plant

Pharmaceutical Commerce

Commercial union

The distribution network covering 31 provinces and municipalities



Import Business

Import scope

- Finish dosage
- Biological products
- Diagnostic products
- Medical equipments
- Medical consumables
- Health products
- Herbal products
- 2nd psychoactive drug

Business model

- General distribution
- Domestic distribution
- Terminal direct sales
- Import business
- Import service..

Service

- Product registration
- Import
- Warehousing
- Logistics
- Bonded and other fully managed customized operation models

Marketing Network

- Hospitals
- Research institutes
- Inspection and quarantine institutions
- Provincial and municipal blood stations
- Research institutes
- Domestic pharmaceutical and medical product distributors and pharmaceutical production enterprises, etc.



Import Businesses

Warehousing and Logistics

We have modern logistics centers in multiple locations and can provide our customers with integrated supply chain and logistics services.

Totally have 41 warehouses located in different main cities in China, cold storage warehouse also available.

Beijing Logistics Center





Import Businesses

On Line Platforms & Cross Border Business

On Line Cross Border Flagship Shop


On Line Flagship Store



Brands we are working with:




Production Bases in China





Integrated Service of Pharmaceutical Commercial Supply Chain in China

China Meheco is a leading medicine, medical device, health product distributor in China. We have vast **terminal coverage**, and a **medicine commercial system** with **industry value chain integration synergy effect**.



Medical institution partners: **20,000+**

Direct sales to Grade 3 A hostitals: **1000+**

Retail pharmacy partners: **16,000+**





Capabilities of Meheco that can Help You Win

- ✓ Central enterprise platform and powerful financing ability
- ✓ Full-fledged business networks and powerful terminal coverage
- ✓ Integrated service platform and quality brand influence
- ✓ Efficient talent team and comprehensive service provider
- ✓ Quality control system and registration support
- ✓ Production facilities and capacity of nearly all kinds of formulation
- ✓ Modern Logistic system and integrated comprehensive services

Product registration

Import, Warehousing, logistics,
and bonded services

Sales & marketing in China
(Production if needed)



中国医药
MEHECO

Contact

Julie Liu / BD Deputy GM

Tel: 0086 10-67108821

Mob: 0086 13681372732 (Whatsapp & Wechat & BOTIM)

Email: liuxiaoyu@mehecointl.com.cn

Skype: julieliu712